CAR-T Cell Therapy Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence

November 14 22:13 2022
CAR-T Cell Therapy Market Size Share Trends Growth Demand and Competitive Analysis Insights 2022-2029 | DataM Intelligence
DataM Intelligence
Global CAR-T Cell Therapy Market is expected to grow at a CAGR of 9.1% during the forecasting period (2022-2029).

Market Overview

Chimeric antigen receptor T-cell remedy, additionally known as CAR-T remedy, is the sort of remedy in which a patient’s T cells were genetically engineered to produce chimeric antigen receptor (CAR) T-cells that are used to recognize most cancers cells to greater correctly target and wreck them. CARs are proteins that allow the T cells to recognize an antigen on specific tumor cells. CAR-T cells may additionally stay in the frame months after the infusion has been completed and assist cancer cells from returning. CAR-T mobile remedy is a promising rising treatment for most cancer sufferers and is more and more favored over chemotherapy, surgical operation, and radiation.

To Download free sample @

Market Dynamics

The worldwide market for the CAR-T Cell Therapy Market is normally pushed by means of the growing incidence of most cancers coupled with excessive demand for an effective remedy for most cancers.

According to the World Health Organization, the global cancer burden is anticipated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in six girls internationally broaden most cancers at some point in their lifetime. Moreover, technological improvements for the dependable treatment of cancer, increasing investments in R&D via essential marketplace players, governmental tasks on treatment and research, and the developing number of humans resistant to chemotherapy and radiation are expected to boost the market boom.

For instance, in May 2019, Ziopharm Oncology Inc., a clinical-stage immuno-oncology enterprise developing subsequent-technology cell and gene cures, signed one of a kind licensing agreement with the National Cancer Institute (NCI) for highbrow assets for the development and commercialization of cellular treatments for cancer with the Company’s Sleeping Beauty platform.

In April 2019, Allogene Therapeutics Inc., a scientific-level biotechnology organization pioneering the development of allogeneic CAR T (AlloCAR T) cures for most cancers, published preclinical study effects of ALLO-715, an AlloCAR T therapy concentrated on B-cellular maturation antigen (BCMA), as a capability novel treatment for a couple of myeloma and different BCMA-high quality malignancies, in Molecular Therapy.

However, the stringent regulations and aspect results main to neurological issues coupled with the high fee of remedy may also prevent market development.

Market Segmentation

By Target Antigen 

  • CD 19
  • CD 20
  • GD2
  • CD22

By Therapeutic Application

  • Acute Lymphoblastic Leukemia (ALL) 
  • Chronic lymphocytic leukemia (CLL) 
  • Non-Hodgkin lymphoma 
  • Acute myeloid leukemia (AML) 

Market Competition

To increase user base and improve their CAR-T Cell Therapy market presence, companies are increasingly launching innovative products, growing FDA approvals, and having a strong pipeline. Several companies have adopted merger and acquisitions policies, geographic expansion, and collaborations to help them to stand out as strong competitors in the market and also expand their sales in the global CAR-T Cell Therapy market.

Major Players in the global CAR-T Cell Therapy market include Novartis International AG, Bluebird Bio, Celgene Corporation, and Gilead Sciences.

In May 2019, Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, announced the United States Food and Drug Administration (FDA) granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma. P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggybac platform technology. The phase II trial of P-BCMA-101 is expected to begin in the second quarter of 2019 with a potential biologics license application filing by the end of 2020.

Trending Topics:

Wearable Asthma Monitoring Devices Market

Epilepsy Monitoring Devices Market

Actigraphy Sensors and PSG Devices Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States